Achaogen Inc (NASDAQ:AKAO) shares shot up 6.5% during trading on Thursday . The stock traded as high as $12.45 and last traded at $12.42. 1,260,539 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 1,853,930 shares. The stock had previously closed at $11.66.

Several brokerages recently commented on AKAO. Guggenheim reiterated a “buy” rating and issued a $14.00 target price on shares of Achaogen in a report on Wednesday. SunTrust Banks dropped their target price on shares of Achaogen to $27.00 and set a “buy” rating on the stock in a report on Wednesday, January 3rd. ValuEngine upgraded shares of Achaogen from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Mizuho reiterated a “buy” rating and issued a $28.00 target price on shares of Achaogen in a report on Wednesday, January 3rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Achaogen in a report on Thursday, November 9th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $25.62.

The company has a quick ratio of 6.99, a current ratio of 6.99 and a debt-to-equity ratio of 0.08. The firm has a market cap of $526.53, a price-to-earnings ratio of -3.70 and a beta of 1.35.

Achaogen (NASDAQ:AKAO) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.13). Achaogen had a negative return on equity of 80.44% and a negative net margin of 593.61%. The company had revenue of $0.58 million for the quarter, compared to the consensus estimate of $2.09 million. During the same quarter in the previous year, the firm posted ($0.41) EPS. The business’s revenue for the quarter was down 96.4% compared to the same quarter last year. analysts expect that Achaogen Inc will post -3.06 earnings per share for the current year.

In related news, major shareholder Robert W. Duggan acquired 50,000 shares of the company’s stock in a transaction dated Friday, January 5th. The shares were bought at an average price of $11.51 per share, for a total transaction of $575,500.00. Following the acquisition, the insider now owns 5,617,752 shares in the company, valued at approximately $64,660,325.52. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Robert W. Duggan acquired 15,000 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The shares were bought at an average price of $10.89 per share, for a total transaction of $163,350.00. Following the acquisition, the insider now owns 5,617,752 shares in the company, valued at approximately $61,177,319.28. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 160,012 shares of company stock worth $1,796,334. Insiders own 8.36% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Point72 Asset Management L.P. boosted its position in shares of Achaogen by 55.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,255,899 shares of the biopharmaceutical company’s stock valued at $35,982,000 after acquiring an additional 806,899 shares in the last quarter. Artal Group S.A. boosted its position in shares of Achaogen by 25.0% during the 3rd quarter. Artal Group S.A. now owns 250,000 shares of the biopharmaceutical company’s stock valued at $3,988,000 after acquiring an additional 50,000 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Achaogen by 68.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 191,670 shares of the biopharmaceutical company’s stock valued at $4,165,000 after acquiring an additional 77,887 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new stake in shares of Achaogen during the 2nd quarter valued at about $1,050,000. Finally, Bank of Nova Scotia acquired a new stake in shares of Achaogen during the 2nd quarter valued at about $1,740,000. Institutional investors and hedge funds own 85.74% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Achaogen (AKAO) Shares Up 6.5%” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/01/12/achaogen-akao-shares-up-6-5.html.

Achaogen Company Profile

Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.